Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 5/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12431131 | 1.00 | PIN1 (0.60) | PIN1TSHRNPSR1KCNQ2CYP11B2 | |
| SCHEMBL1400973 | 1.00 | PIN1 (0.60) | PIN1TSHRNPSR1KCNQ2CYP11B2 | |
| SCHEMBL2790690 | 1.00 | PIN1 (0.60) | PIN1TSHRNPSR1KCNQ2CYP11B2 | |
| Hydrochloric Acid SCHEMBL7213722 | 0.98 | PIN1 (0.58) | PIN1TSHRNPSR1KCNQ2CYP11B2 | |
| SCHEMBL11215754 | 0.98 | PIN1 (0.58) | PIN1TSHRNPSR1KCNQ2CYP11B2 | |
| SCHEMBL2792830 | 0.89 | HTT (0.54) | PIN1TSHRNPSR1HTT | |
| SCHEMBL2796237 | 0.89 | HTT (0.54) | PIN1TSHRNPSR1HTT | |
| SCHEMBL29608780 | 0.89 | HTT (0.54) | PIN1TSHRNPSR1HTT | |
| SCHEMBL29706163 | 0.89 | HTT (0.54) | PIN1TSHRNPSR1HTT | |
| SCHEMBL242244 | 0.89 | HTT (0.54) | PIN1TSHRNPSR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 827 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279170-A1 | CHIRAL-SUBSTITUTED POLY-N-VINYLPYRROLIDINONES AND COMPLEXES WITH BIMETALLIC NANOCLUSTERS AND USES THEREOF | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2023-09-07 | — | — | US | claimed |
| CN-101397247-B | Indan-1-carboxylic acid synthesis method of bulk drug for clidanic acid | UNIV TIANJIN | 2012-05-16 | — | — | CN | claimed |
| US-7863308-B2 | Substituted thiophenes | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-01-04 | — | — | US | claimed |
| CN-101730694-A | Substituted deuterium enriched thiophenes for the treatment of hypertension | AUSPEX PHARMACEUTICALS INC | 2010-06-09 | — | — | CN | claimed |
| EP-2144903-A1 | SUBSTITUTED DEUTERIUM ENRICHED THIOPHENES FOR THE TREATMENT OF HYPERTENSION | Auspex Pharmaceuticals Inc. (US) | 2010-01-20 | — | — | EP | claimed |
| EP-2132199-A1 | SUBSTITUTED PYRIMIDINES | Auspex Pharmaceuticals Inc. (US) | 2009-12-16 | — | — | EP | claimed |
| CN-101397247-A | Method for synthesizing raw medicine dihydroindene-1-carboxyl acid for clidabac | UNIV TIANJIN (CN) | 2009-04-01 | — | — | CN | claimed |
| WO-2008124803-A1 | SUBSTITUTED DEUTERIUM ENRICHED THIOPHENES FOR THE TREATMENT OF HYPERTENSION | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | claimed |
| US-20080255036-A1 | Deuterated thiophene derivatives such as d2-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide; for modulating endothelin receptors; for treating, preventing, or ameliorating one or more symptoms of an endothelin-mediated disorder | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | US | claimed |
| WO-2008122020-A1 | SUBSTITUTED PYRIMIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-09 | — | — | WO | claimed |
| US-20080242687-A1 | SUBSTITUTED PYRIMIDINES | AUSPEX PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | US | claimed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| CN-86103879-A | Provide the method for 2-arylpropionic acid for oneself | — | 1987-04-08 | — | — | CN | claimed |
| US-4416879-A | CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-22 | — | — | US | claimed |
| EP-0007319-B1 | INDAN-1-CARBOXYLIC ACID DERIVATIVES,PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE COMPOUNDS | SCHERING AKTIENGESELLSCHAFT (DE) | 1981-09-16 | — | — | EP | claimed |
| JP-53132549-A | — | — | None | — | — | JP | disclosed |
| JP-54119442-A | — | — | None | — | — | JP | disclosed |
| US-3886207-A | Process for producing indan-1-carboxylic acid derivatives | TAKEDA CHEMICAL INDUSTRIES LTD | 1975-05-27 | — | — | US | disclosed |
| US-3886207-A | Process for producing indan-1-carboxylic acid derivatives | TAKEDA CHEMICAL INDUSTRIES LTD | 1975-05-27 | — | — | US | disclosed |
| US-3870752-A | ACYL SUBSTITUTED INDANE CARBOXYLIC ACIDS | SANDOZ AG | 1975-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | PIN1 2745/4885TSHR 1495/4885NPSR1 22/4885 |
| US-20080255036-A1 | Deuterated thiophene derivatives such as d2-2-[2-(6-methyl-benzo[1,3]dioxol-5-yl)-acetyl]-thiophene-3-sulfonic acid (4-chloro-3-methyl-isoxazol-5-yl)-amide; for modulating endothelin receptors; for treating, preventing, or ameliorating one or more symptoms of an endothelin-mediated disorder | EDNRA, EDNRB, TBXA2R | PIN1 4810/4885TSHR 107/4885NPSR1 33/4885 |
| US-20080242687-A1 | SUBSTITUTED PYRIMIDINES | EDNRB, EDNRA, ECE1 | PIN1 4392/4885TSHR 3210/4885NPSR1 281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.